ORPHA:963
Acromegaly
Publications
24,055
98.4th percentile
Trials
115
Interventional, condition-specific
Researchers
1,210
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare acquired endocrine disease related to excessive production of growth hormone (GH) and characterized by somatic disfigurement (mainly involving the face and extremities) and systemic manifestations.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019933
- MeSH:D000172
- UMLS:C0001206
- NCIT:C84533
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
24,055 matched papers (8,626 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
115 matched on ClinicalTrials.gov (7 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
24,055
24,055 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
24,055 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
8,626 in the last 10 years · medium confidence · 98.4th percentile (publications denominator)
Phrase hits: 24,055 · MeSH hits: 0
Who's working on it?
1,210
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Chiloiro S8 papers · 2026
School of Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy. sabrina.chiloiro@unicatt.it.
Papers in Europe PMC - 02Biagetti B7 papers · 2026
Endocrinology & Nutrition Department, Hospital Universitario Vall de Hebrón, CIBERER U747 (ISCIII), Barcelona, Spain.
Papers in Europe PMC - 03Bianchi A7 papers · 2026
School of Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
Papers in Europe PMC - 04De Marinis L7 papers · 2026
School of Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
Papers in Europe PMC - 05Giampietro A7 papers · 2026
School of Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
Papers in Europe PMC - 06Pontecorvi A7 papers · 2026
School of Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
Papers in Europe PMC - 07Araujo-Castro M6 papers · 2026
Endocrinology & Nutrition Department, Hospital Universitario Ramón y Cajal, Spain & Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Madrid, Spain.
Papers in Europe PMC - 08Fleseriu M6 papers · 2026
Departments of Medicine (Division of Endocrinology, Diabetes and Clinical Nutrition) and Neurological Surgery, Pituitary Center, Oregon Health & Science University, 3303 SW Bond Ave, Portland, OR, 97239, USA. fleseriu@ohsu.edu.
Papers in Europe PMC - 09Giustina A6 papers · 2026
Institute of Endocrine and Metabolic Sciences, Università Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy.
Papers in Europe PMC - 10Marazuela M6 papers · 2026
Department of Endocrinology and Nutrition, La Princesa University Hospital, 28006 Madrid, Spain.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
115
interventional trials for this specific condition
115 interventional trials matched this specific condition name; 7 currently recruiting in our sample.
Data as of 27 July 2026
115 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 98.6th percentile).
medium confidence · 98.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
115 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06949891·RECRUITING·KETOgenic Diet Therapy in Patients With ACROmegaly
Conditions: Acromegaly Due to Pituitary Adenoma · Ketogenic Diet · Mediterranean Diet·Matched via name phrase
- NCT07641179·NOT YET RECRUITING·A Study to Evaluate MAR002 for Acromegaly
Conditions: Acromegaly·Matched via name phrase
- NCT07195175·RECRUITING·Study of MAR002 in Healthy Men
Conditions: Acromegaly·Matched via name phrase
- NCT07037420·RECRUITING·ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
Conditions: Acromegaly·Matched via name phrase
- NCT07663318·NOT YET RECRUITING·A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)
Conditions: Acromegaly·Matched via name phrase
- NCT07623824·NOT YET RECRUITING·A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly
Conditions: Diagnosed With Acromegaly, Currently in the Active Stage of the Disease·Matched via name phrase
- NCT06930625·RECRUITING·A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
Conditions: Acromegaly·Matched via name phrase
Observational and natural-history studies
83 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT00461188·RECRUITING·Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA
Conditions: Acromegaly · Gigantism · Familial Isolated Pituitary Adenoma · FIPA·Matched via name phrase
- NCT00001595·RECRUITING·An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
Conditions: Panhypopituitarism · Gigantism/Acromegaly · Prolactinoma · Cushing Disease·Matched via name phrase
- NCT06344650·RECRUITING·Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess.
Conditions: Acromegaly·Matched via name phrase
- NCT03042026·RECRUITING·Developing a Simple Recognition System of Acromegaly
Conditions: Acromegaly·Matched via name phrase
- NCT06326853·NOT YET RECRUITING·Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models
Conditions: Endocrine Disorders · Adiposity · Pituitary Adenoma · Cushing Syndrome·Matched via name phrase
- NCT03158090·RECRUITING·The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research
Conditions: Acromegaly·Matched via name phrase
- NCT07179926·RECRUITING·Effects of Pasireotide Lar Therapy on Bone Metabolism
Conditions: Acromegaly Due to Pituitary Adenoma · Acromegaly·Matched via name phrase
- NCT06597383·RECRUITING·The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In Acromegaly
Conditions: Acromegaly·Matched via name phrase
- NCT07659912·NOT YET RECRUITING·Direct Versus Video Laryngoscopy in Patients With Acromegaly
Conditions: Acromegaly · Nonfunctioning Pituitary Adenoma·Matched via name phrase
- NCT07583563·RECRUITING·An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
Conditions: Acromegaly·Matched via name phrase
- NCT05964712·RECRUITING·Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study
Conditions: Acromegaly·Matched via name phrase
- NCT07306325·NOT YET RECRUITING·Ultrasound in Predicting Difficult Intubation in Acromegaly Patients
Conditions: Acromegaly Due to Pituitary Adenoma · Difficult Intubation · Airway Ultrasonography·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Acromegaly"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Acromegaly"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 115 interventional · 83 observational · 1 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T16:01:32.899Z
